Overlooked during the global fixation on vaccinations: oral antivirals pills.
A pill-based “Tamiflu approach” would be easier than current therapies like monoclonal antibodies and convalescent plasma that need intravenous infusions.
Tantalizing Advantage: An antiviral could block SARS-CoV-2’s replication and ”provide broad spectrum coverage against emerging SARS-CoV-2 variants,” a MedPage Today article notes.
In the works now:
- Molnupiravir, which knocked out measurable virus in 5 days in a 175-person phase II trial
- Upamostat in a phase II/III trial
- AT-527 for “mild to moderate COVID-19 in the outpatient setting” in phase II.